姜油酮联合索拉非尼对人肝癌HepG2细胞迁移和侵袭的抑制作用

doi:10.13481/j.1671-587x.20190203

摘要/Abstract

摘要： 目的：探讨姜油酮联合索拉非尼对人肝癌HepG2细胞迁移和侵袭的影响，并阐明其相关作用机制。方法：采用不同浓度姜油酮和索拉非尼单独或联合对人肝癌HepG2细胞进行干预，MTT法检测细胞增殖率，根据其结果选择姜油酮和索拉非尼的适合浓度。实验分为对照组（DMSO）、姜油酮组（30μmol·L^-1）、索拉非尼组（3 μmol·L^-1）和联合组（姜油酮30 μmol·L^-1+索拉非尼3μmol·L^-1），采用细胞划痕实验检测各组HepG2细胞划痕愈合率，Transwell实验检测各组HepG2细胞穿膜细胞数，Western blotting法检测各组HepG2细胞中基质金属蛋白酶2（MMP-2）和基质金属蛋白酶9（MMP-9）蛋白表达水平。结果：MTT实验，与对照组比较，姜油酮组和联合组细胞增殖率明显降低（P<0.01）。细胞划痕实验，与对照组比较，姜油酮组和索拉非尼组HepG2细胞划痕愈合率降低（P<0.05）；与姜油酮组和索拉非尼组比较，联合组HepG2细胞划痕愈合率明显降低（P<0.01）。Transwell实验，与对照组比较，姜油酮组和索拉非尼组HepG2细胞穿膜细胞数减少（P<0.05）；与姜油酮组和索拉非尼组比较，联合组穿膜细胞数明显降低（P<0.01）。Western blotting法检测，与对照组比较，姜油酮组和索拉非尼组HepG2细胞中MMP-2和MMP-9蛋白表达水平降低（P<0.05）；与姜油酮组和索拉非尼组比较，联合组HepG2细胞中MMP-2和MMP-9蛋白表达水平明显降低（P<0.01）。结论：姜油酮可通过降低HepG2细胞中MMP-2和MMP-9蛋白表达来抑制人肝癌细胞迁移和侵袭能力，且与索拉非尼联用效果更佳。

关键词: 肝肿瘤, 姜油酮, 索拉非尼, 细胞迁移, 细胞侵袭

Abstract: Objective: To explore the inhibitory effects of zingerone in combination with sorafenib on the migration and invasion of human liver cancer HepG2 cells, and to clarify their relative mechanisms.Methods: The HepG2 cells were treated with different concentrations of zingerone and sorafenib alone or in combination. The cellpoliferation rate was determined by MTT assay. The appropriate concentrations of zingerone and sorafenib were selected according to the results. The experiment was divided into control group (DMSO), zingerone group (30μmol·L^-1), sorafenib group (3 μmol·L^-1) and combination group (zingerone 30 μmol·L^-1+ sorafenib 3μmol·L^-1).The scratch healing rate was measured by cell wound healing test;Transwell assay was used to detect the number of transmembrane cells in each group. The expression levels of MMP-2 and MMP-9 were determined by Western blotting method.Results: Compared with control group, the proliferation rates of the HepG2 cells in zingerone group and combination group were significantly decreased (P<0.01). Compared with control group,the scratch healing rates of the HepG2 cells in zingerone group and sorafenib group were reduced (P<0.05);the scratch healing rate in combination group was significantly lower than those in zingerone group and sorafenib group (P<0.01). In the Transwell experiment, the number of transmembrane cells in zingerone group and sorafenib group was decreased compared with control group (P<0.05);the number of transmembrane cells in combination group was significantly lower than those in zingerone group and sorafenib group(P<0.01).The Western blotting results showed the expression levels of MMP-2 and MMP-9 in the HepG2 cells in zingerone group and sorafenib group were lower than those in control group (P<0.05),and the expression levels of MMP-2 and MMP-9 in combination group were significantly lower than those in zingerone group and sorafenib group (P<0.01).Conclusion: Zingerone can inhibit the migration and invasion of the human hepatoma cells by decreasing the expressions of MMP-2 and MMP-9 proteins in the HepG2 cells, and it has better effect with sorafenib.

Key words: liver neoplasms, zingerone, sorafenib, cell migration, cell invasion

中图分类号:

R735.7

徐振华, 苏荣健. 姜油酮联合索拉非尼对人肝癌HepG2细胞迁移和侵袭的抑制作用[J]. 吉林大学学报(医学版), 2019, 45(02): 228-233.

XU Zhenhua, SU Rongjian. Inhibitory effects of zingerone combined with sorafenib on migration and invasion of human liver cancer HepG2 cells[J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 228-233.

参考文献

[1] OOKA Y, MIHO K, SHUNTARO O, et al. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection[J]. Hepatol Int,2018,12(6):523-530.
[2] LEE S, CHO Y Y, CHO E J, et al. Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK[J]. Int J Mol Med,2018, 42(5):2551-2559.
[3] LO J, LAU E Y, CHING R H, et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice[J]. Hepatology,2015,62(2):534-545.
[4] WEE S L, PEEK T, CLARKE A R. The responsiveness of Bactrocera jarvisi (Diptera:Tephritidae) to two naturally occurring phenylbutaonids, zingerone and raspberry ketone[J]. J Insect Physiol,2018,109:41-46.
[5] CUI Y, SHI Y, BAO Y, et al. Zingerone attenuates diabetic nephropathy through inhibition of nicotinamide adenine dinucleotide phosphate oxidase 4[J]. Biomed Pharmacother, 2018,99:422-430.
[6] KIM Y J, JEON Y, KIM T, et al. Combined treatment with zingerone and its novel derivative synergistically inhibits TGF-β1 induced epithelial-mesenchymal transition, migration and invasion of human hepatocellular carcinoma cells[J]. Bioorg Med Chem Lett, 2017,27(4):1081-1088.
[7] RAOUL J L, KUDO M, FINN R S, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma:Sorafenib and beyond[J]. Cancer Treat Rev,2018,68:16-24.
[8] CHOWDHURY S M, LEE T, BACHAWAL S V, et al. Longitudinal assessment of ultrasound-guided complementary microRNA therapy of hepatocellular carcinoma[J]. J Control Release,2018,281:19-28.
[9] 乔宪伟, 王柯萌, 杨月娥. 索拉非尼对中晚期肝癌介入治疗患者生存率及不良反应的临床疗效分析[J]. 北方药学,2018,15(7):158.
[10] URIARTE I, INSAUSTI A, COCINERO E J, et al. Competing dispersive interactions:From small energy differences to large structural effects in methyl jasmonate and zingerone[J]. J Phys Chem Lett,2018,9(20):5906-5914.
[11] ERNST E, PITTLER M H. Efficacy of ginger for nausea and vomiting:a systematic review of randomized clinical trials[J]. Br J Anaesth,2000,84(3):367-371.
[12] PALATTY P L, HANIADKA R, VALDER B,et al. Ginger in the prevention of nausea and vomiting:a review[J]. Crit Rev Food Sci Nutr,2013,53(7):659-669.
[13] MIN G, KU S K, LEE T, et al. Suppressive effects of zingerone on TGFBIp-mediated septic responses[J]. Arch Pharm Res,2018,41(3):276-287.
[14] KANDEMIR F M, YILDIRIM S, KUCUKLER S, et al. Therapeutic efficacy of zingerone against vancomycin-induced oxidative stress, inflammation, apoptosis and aquaporin 1 permeability in rat kidney[J]. Biomed Pharmacother,2018,105:981-991.
[15] LEE J, OH S W, SHIN S W, et al. Zingerone protects keratinocyte stem cells from UVB-induced damage[J]. Chem Biol Interact,2018,279:27-33.
[16] CHOI J S, RYU J, BAE W Y, et al. Zingerone suppresses tumor development through decreasing cyclin D1 expression and inducing mitotic arrest[J]. Int J Mol Sci,2018,19(9):E2832.
[17] HE X X, SHI L L, QIU M J, et al. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families[J]. Biochem Biophys Res Commun,2018,504(4):878-884.
[18] 刘霞, 齐凤杰, 杜晓媛. 沉默CRAF基因表达对肝癌细胞侵袭和迁移的影响[J]. 吉林大学学报:医学版, 2018,44(3):521-525.
[19] 杨安强, 杨晓滨, 李平,等. 脑膜瘤组织中CLDN₆基因表达量与MMPs/TIMPs、EMT基因表达量的相关性研究[J]. 海南医学院学报,2017,23(17):2419-2422.
[20] ZHOU M, LIU X J, LI Z H, et al. Caspase-3 regulates the migration, invasion and metastasis of colon cancer cells[J]. Int J Cancer,2018,143(4):921-930.
[21] 芮昆昆, 章波, 邰小华,等. 基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J]. 医学信息,2018, 31(3):21-24.
[22] 李杰, 肖达, 李智奇. 基质金属蛋白酶9基因在肝癌细胞株、肝细胞肝癌组织中的表达及意义[J]. 中国卫生工程学,2018,17(3):351-353.
[23] 陈小梦,闫昊,左子欣,等.癌组织中MMP-9的表达对食管癌诊断价值的meta分析[J].郑州大学学报:医学版,2018,53(5):642-647.
[24] 陈薇,陈靖,游佳,等.MMP-9及glypican-3在肝癌组织中的表达及其临床病理价值[J].西安交通大学学报:医学版,2018,39(3):392-395.
[25] STUELTEN C H, PARENT C A, MONTELL D J. Cell motility in cancer invasion and metastasis:insights from simple model organisms[J]. Nat Rev Cancer,2018,18(5):296-312.